BRPI0415204A - construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada - Google Patents
construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificadaInfo
- Publication number
- BRPI0415204A BRPI0415204A BRPI0415204-2A BRPI0415204A BRPI0415204A BR PI0415204 A BRPI0415204 A BR PI0415204A BR PI0415204 A BRPI0415204 A BR PI0415204A BR PI0415204 A BRPI0415204 A BR PI0415204A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- particle
- delivery device
- mediated delivery
- promoter sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50993603P | 2003-10-10 | 2003-10-10 | |
| PCT/GB2004/004279 WO2005035771A2 (en) | 2003-10-10 | 2004-10-11 | Nucleic acid constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415204A true BRPI0415204A (pt) | 2006-12-05 |
Family
ID=34435038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415204-2A BRPI0415204A (pt) | 2003-10-10 | 2004-10-11 | construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8663657B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1685251B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4814099B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101234981B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1890375B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004279991B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0415204A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2542288A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1685251T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA010056B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2457022T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174848A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06003978A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20062080L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ546554A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1685251T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1685251E (cg-RX-API-DMAC7.html) |
| SG (1) | SG147430A1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI1685251T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005035771A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200603685B (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
| US20100160415A1 (en) * | 2005-10-05 | 2010-06-24 | Bayhill Therapeutics, Inc | Compositions and methods for treatment of autoimmune disease |
| AU2009273239B2 (en) | 2008-07-23 | 2015-07-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel regulatory elements |
| SI2506857T1 (en) | 2009-12-01 | 2018-08-31 | Translate Bio, Inc. | Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| CN101993878B (zh) * | 2010-10-14 | 2012-04-18 | 南京农业大学 | 一种rRNA嵌合启动子及含有该嵌合启动子的表达载体 |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013143698A1 (en) * | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| ES2660129T3 (es) | 2012-03-27 | 2018-03-20 | Curevac Ag | Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| HUE026516T2 (en) | 2012-09-24 | 2016-06-28 | Lonza Biologics Plc | Expression vectors containing chimeric cytomegalovirus promoter and enhancer sequences |
| WO2014102101A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| EP2938725B1 (en) | 2012-12-31 | 2017-08-23 | Boehringer Ingelheim International GmbH | Heterologous intron within an immunoglobulin domain |
| WO2014102103A2 (en) | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Heterologous intron within a signal peptide |
| EP2938728B1 (en) * | 2012-12-31 | 2020-12-09 | Boehringer Ingelheim International GmbH | Artificial introns |
| KR102311614B1 (ko) | 2013-03-14 | 2021-10-08 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
| AU2014375402B2 (en) * | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
| CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
| EP4729528A3 (en) | 2014-04-25 | 2026-06-24 | Translate Bio, Inc. | Methods for purification of messenger rna |
| SG11201609879SA (en) * | 2014-06-18 | 2016-12-29 | Agency Science Tech & Res | Novel promoters for high level expression |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| US20200377887A1 (en) * | 2017-09-22 | 2020-12-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| AU2019384557B2 (en) | 2018-11-21 | 2025-07-17 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CA3155003A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| TWI871709B (zh) | 2020-06-21 | 2025-02-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3431140A1 (de) * | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
| US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
| US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| TW404844B (en) * | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| WO1995019799A1 (en) * | 1994-01-21 | 1995-07-27 | Agracetus, Inc. | Gas driven gene delivery instrument |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| DE69624815T2 (de) * | 1995-05-24 | 2003-07-10 | Hawaii Biotech Group | Untereinheitsimpfstoff gegen flavivirus infektion |
| US6110707A (en) * | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
| GB9715064D0 (en) * | 1997-07-17 | 1997-09-24 | Ppl Therapeutics Scotland Ltd | Protein expression |
| US20020106635A1 (en) | 1998-05-27 | 2002-08-08 | Bruce Freimark | Cytokine resistant cytomegalovirus promoter mutants and related products and methods |
| JP2002527527A (ja) | 1998-10-19 | 2002-08-27 | パウダージェクト ヴァクシンズ,インコーポレイテッド | 最小プロモーターおよびその使用 |
| WO2001058483A2 (en) | 2000-02-08 | 2001-08-16 | The University Of Virginia Patent Foundation | METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
| US20030124523A1 (en) * | 2000-06-22 | 2003-07-03 | Asselbergs Fredericus Alphonsus Maria | Organic compounds |
| CN1247785C (zh) | 2000-10-13 | 2006-03-29 | 希龙公司 | 巨细胞病毒内含子a片段 |
| ATE442858T1 (de) | 2000-11-27 | 2009-10-15 | Powderject Vaccines Inc | Nukleinsäureadjuvantien |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| BR0209854A (pt) | 2001-05-18 | 2004-06-08 | Powderject Vaccines Inc | Molécula de ácido nucléico recombinante, cassete de expressão, vetor, polipeptìdeo, composição de vacina, dispositivo de aceleração de partìcula, e, método para gerar uma resposta imune celular em um indivìduo |
| GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
| WO2005035779A2 (en) | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc | Method |
| GB0507997D0 (en) * | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
-
2004
- 2004-10-11 WO PCT/GB2004/004279 patent/WO2005035771A2/en not_active Ceased
- 2004-10-11 JP JP2006530599A patent/JP4814099B2/ja not_active Expired - Fee Related
- 2004-10-11 SG SG200807573-1A patent/SG147430A1/en unknown
- 2004-10-11 NZ NZ546554A patent/NZ546554A/en not_active IP Right Cessation
- 2004-10-11 BR BRPI0415204-2A patent/BRPI0415204A/pt active Search and Examination
- 2004-10-11 EP EP04768811.4A patent/EP1685251B1/en not_active Expired - Lifetime
- 2004-10-11 PT PT47688114T patent/PT1685251E/pt unknown
- 2004-10-11 US US10/575,087 patent/US8663657B2/en not_active Expired - Fee Related
- 2004-10-11 PL PL04768811T patent/PL1685251T3/pl unknown
- 2004-10-11 KR KR1020117024399A patent/KR101234981B1/ko not_active Expired - Fee Related
- 2004-10-11 ES ES04768811.4T patent/ES2457022T3/es not_active Expired - Lifetime
- 2004-10-11 SI SI200432144T patent/SI1685251T1/sl unknown
- 2004-10-11 DK DK04768811.4T patent/DK1685251T3/en active
- 2004-10-11 CA CA002542288A patent/CA2542288A1/en not_active Abandoned
- 2004-10-11 MX MXPA06003978A patent/MXPA06003978A/es active IP Right Grant
- 2004-10-11 CN CN2004800367871A patent/CN1890375B/zh not_active Expired - Fee Related
- 2004-10-11 AU AU2004279991A patent/AU2004279991B2/en not_active Ceased
- 2004-10-11 EA EA200600746A patent/EA010056B1/ru not_active IP Right Cessation
- 2004-10-11 KR KR1020067009012A patent/KR101225395B1/ko not_active Expired - Fee Related
-
2006
- 2006-04-06 IL IL174848A patent/IL174848A/en active IP Right Review Request
- 2006-05-09 ZA ZA200603685A patent/ZA200603685B/en unknown
- 2006-05-09 NO NO20062080A patent/NO20062080L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1890375B (zh) | 2011-12-07 |
| IL174848A (en) | 2011-06-30 |
| DK1685251T3 (en) | 2014-03-24 |
| NO20062080L (no) | 2006-05-09 |
| CA2542288A1 (en) | 2005-04-21 |
| KR20110120364A (ko) | 2011-11-03 |
| SG147430A1 (en) | 2008-11-28 |
| WO2005035771A2 (en) | 2005-04-21 |
| US20080160048A1 (en) | 2008-07-03 |
| EP1685251A2 (en) | 2006-08-02 |
| KR101234981B1 (ko) | 2013-02-21 |
| KR101225395B1 (ko) | 2013-01-28 |
| PT1685251E (pt) | 2014-04-15 |
| AU2004279991B2 (en) | 2010-11-25 |
| PL1685251T3 (pl) | 2014-07-31 |
| JP2007509607A (ja) | 2007-04-19 |
| ZA200603685B (en) | 2007-09-26 |
| SI1685251T1 (sl) | 2014-05-30 |
| EA010056B1 (ru) | 2008-06-30 |
| JP4814099B2 (ja) | 2011-11-09 |
| EA200600746A1 (ru) | 2006-10-27 |
| WO2005035771A3 (en) | 2005-08-25 |
| EP1685251B1 (en) | 2014-03-05 |
| MXPA06003978A (es) | 2006-06-27 |
| NZ546554A (en) | 2009-04-30 |
| CN1890375A (zh) | 2007-01-03 |
| ES2457022T3 (es) | 2014-04-24 |
| IL174848A0 (en) | 2006-08-20 |
| KR20060125742A (ko) | 2006-12-06 |
| AU2004279991A1 (en) | 2005-04-21 |
| US8663657B2 (en) | 2014-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirai et al. | Degradation of transcription factors, c‐Jun and c‐Fos, by calpain | |
| Temeles et al. | Yeast and mammalian ras proteins have conserved biochemical properties | |
| Presland et al. | Epithelial structural proteins of the skin and oral cavity: function in health and disease | |
| Saltzman et al. | Promoter specificity and modulation of RNA polymerase II transcription | |
| Sekiguchi et al. | Human liver fibronectin complementary DNAs: identification of two different messenger RNAs possibly encoding the. alpha. and. beta. subunits of plasma fibronectin | |
| Serrano et al. | Localization of the tubulin binding site for tau protein | |
| BRPI0607119A2 (pt) | construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse | |
| Tong et al. | cDNA clones reveal differences between human glial and endothelial cell platelet-derived growth factor A-chains | |
| Ting et al. | The nucleotide sequence encoding the hamster 78-kDa glucose-regulated protein (GRP78) and its conservation between hamster and rat | |
| WO2003012050A3 (en) | Mitochondrial genome replenishment | |
| BRPI0514680A (pt) | produção de anticorpos anti-amilóide beta | |
| US20070292904A1 (en) | Ephrin and EPH receptor mediated immune modulation | |
| SG147430A1 (en) | Nucleic acid constructs | |
| CA2219821A1 (en) | Compositions for expression of proteins in host cells using a preprocollagen signal sequence | |
| CN1051934A (zh) | 在真核细胞中表达神经生长因子的基因构建物的制备方法 | |
| DK0973794T3 (da) | Netrinreceptorer | |
| Michaud et al. | Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3 | |
| DE60016256D1 (de) | Mutierte anthraxtoxin schutz-antigenproteinen spezifisch für zellen die hohe zell-oberfläachemetalloproteinasen-oder plasminogenaktivator-rezeptoren-menge enthalten | |
| ATE373708T1 (de) | Ein homeobox-faktor der insulin-expression in pankreatischen inselnzellen stimuliert | |
| Hisato et al. | Expression of the chicken ‘δ2-cry stallin’gene in mouse cells: evidence for encoding of argininosuccinate lyase | |
| SE9801148D0 (sv) | New receptors | |
| ITRM950273A1 (it) | Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni | |
| AR032557A1 (es) | Secuencias reguladoras en plantas | |
| AR016263A1 (es) | Un constructo de adn que altera la expresion de un gen g-csf endogeno en una celula de mamifero en la integracion al genoma de la celula a traves derecombinacion homologa, una celula recombinante homologamente establemente transfectada con el constructo de adn, un metodo de alteracion de la expresio | |
| Mäkinen et al. | New World, but not Old World, monkeys carry several genes encoding β‐microseminoprotein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |